DIFFERENTIAL EXPRESSION PATTERN OF AIP, UCKL1, AND PKN1 GENES IN PROSTATE CANCER PATIENTS
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17380Keywords:
AIP, bioinformatic analysis, expression pattern, PKN1, prostate cancer, UCKL1Abstract
Background: The evolution of research on the therapy of prostate cancer (PC) depends on a study of molecules that are involved in the progression of this disease. Nevertheless, there is a need for additional biomarkers that would help to refine the molecular profile of PC and propose the personalized therapeutic approach. Aim: To study differential expression patterns of the AIP, UCKL1, and PKN1 genes in blood sera and tumor tissue of patients with PC with different Gleason scores. Materials and Methods: The total extracellular RNA was isolated from blood sera of 44 PC patients and 4 healthy donors. cDNAs were synthesized and quantitative polymerase chain reaction (qPCR) was performed. Immunohistochemical study of the UCKL, AIP and PKN1 proteins was performed on deparaffinized sections of tumors. The study was supplemented by a bioinformatic analysis of the publicly available databases. Results: The UCKL1, AIP, PKN1 genes were overexpressed at the mRNA level in blood sera of PC patients, compared to healthy donors. Extracellular mRNA levels of AIP and UCKL-1 were 100-1000-fold increased in all PC samples compared to the healthy donors but without significant inequality between the groups of PC cases differing by the Gleason score. The highest levels were detected in the samples from PC patients with the Gleason score > 9. The PKN1 expression was higher in PC patients compared with healthy donors but without significant difference between the groups. Conclusions: From the three chosen genes, AIP and UCKL1 showed similar pattern of expression assessed either by extracellular mRNA levels in patient sera or the protein in PC tissues. AIP was up to 1000-fold increased in all PC samples, compared to the healthy donors, with the highest levels in PC cases with Gleason score > 9. Expression levels of the AIP and UCKL1 genes in the PC patient sera may be used as an additional criterion for prognosis of tumor progression.
References
Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev 2018; 32: 1105–40. https://doi.org/10.1101/gad.315739.118
Fedorenko Z, Michailovich Yu, Goulak L, et al. Cancer in Ukraine 2019–2020: Incidence, mortality, prevalence and other relevant statistics. Bull Nat Cancer Reg Ukraine 2021; 22.
Humphrey PA. Histopathology of prostate cancer. Cold Spring Harb Perspect Med 2017; 7: a030411. https://doi.org/10.1101/cshperspect.a030411
Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs — Part B: Prostate and bladder tumours. Eur Urol 2016; 70: 106–19. https://doi.org/10.1016/j.eururo.2016.02.028
Turnham DJ, Bullock N, Dass MS The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 2020; 9: 2342. https://doi.org/10.3390/cells9112342
Fonseca-Alves CE, Kobayashi PE, Rivera Caldero´n LG, et al. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression. PLoS One 2018; 13: e0199173. https://doi.org/10.1371/journal.pone.0199173
Papachristodoulou A, Rodriguez-Calero A, Panja S, et al. NKX3.1 localization to mitochondria suppresses prostate cancer initiation. Cancer Discov 2021; 11: 2316–33. https://doi.org/10.1158/2159-8290.CD-20-1765
Dariane C, Clairefond S, Péant B, et al. High keratin-7 expression in benign peritumoral prostatic glands is predictive of bone metastasis onset and prostate cancer-specific mortality. Cancers 2022; 14: 1623. https://doi.org/10.3390/cancers14071623
Ilka K, Carsten S, Klaus J, et al. Sensitivity of HOXB13 as a diagnostic immunohistochemical marker of prostatic origin in prostate cancer metastases: comparison to PSA, prostein, androgen receptor, ERG, NKX3.1, PSAP, and PSMA. Int J Mol Sci 2017; 18: 1151. https://doi.org/10.3390/ijms18061151
Zadvornyi TV, Lukianova NYu, Borikun TV, et al. NANOG as prognostic factor of prostate cancer course. Exp Oncol 2020; 42: 94–100. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14673
Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med 2015; 4: 1033–43. https://doi.org/10.5966/sctm.2015-0048
Li C, Liu S, Yan R, et al. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. Theranostics 2017; 7: 67–80. https://doi.org/10.7150/thno.16752
Kovalevska L, Kashuba E, Zadvornyj T. Differential expression patterns of AIP, UCKL1, and PKN1 genes in breast cancer of different molecular subtypes. Exp Oncol 2021; 43: 298–305. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17067
Hernández-Ramírez LC, Morgan RML, Barry S, et al. Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. Oncotarget 2018; 9: 9177–98. https://doi.org/10.18632/oncotarget.24183
Wang C, Cui A, Bukenya M, et al. Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell Rep 2021; 37: 110021. https://doi.org/10.1016/j.celrep.2021.110021
Przybyla T, Sakowicz-Burkiewicz M, Maciejewska I, et al. Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil. Acta Biochim Pol 2017; 64: 315–22. https://doi.org/10.18388/abp.2016_1421
Buivydiene A, Liakina V, Valantinas J, et al. expression levels of the uridine-cytidine kinase like-1 protein as a novel prognostic factor for hepatitis C virus-associated hepatocellular carcinomas. Acta Naturae 2017; 9: 108–14.
Buivydiene A, Liakina V, Kashuba E, et al. Impact of the Uridine(-)Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the development of hepatocellular carcinoma in cirrhotic chronic hepatitis C patients-A pilot study. Medicina (Kaunas) 2018; 54: 67. https://doi.org/10.3390/medicina54050067
Kashuba E, Kashuba V, Sandalova T, et al. Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase. BMC Cell Biol 2002; 3: 23. https://doi.org/10.1186/1471-2121-3-23
Wang X, Ge Y, Shi M, et al. Protein kinase N1 promotes proliferation and invasion of liver cancer. Exp Ther Med 2021; 21: 651. https://doi.org/10.3892/etm.2021.10083
Jilg CA, Ketscher A, Metzger E, et al. PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget 2014; 5: 12646–64. https://doi.org/10.18632/oncotarget.2653
Kovalevska LM, Zadvornyj TV, Malysheva TA, et al. Study on relative gene expression levels in tumor tissue and in blood serum of cancer patients. Oncologiya 2021, 23: 149–53 (in Ukrainian). https://doi.org/10.32471/oncology.2663-7928.t-23-3-2021-g.9761
Di Vizio D, Morello M, Dudley AC, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012; 181: 1573–84. https://doi.org/10.1016/j.ajpath.2012.07.030
Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol 2015; 40: 41–51. https://doi.org/10.1016/j.semcdb.2015.02.010
Sadik N, Cruz L, Gurtner A, et al. Extracellular RNAs: a new awareness of old perspectives. Methods Mol Biol 2018; 1740: 1–15. https://doi.org/10.1007/978-1-4939-7652-2_1
Yuan T, Huang X, Woodcock M, et al. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep 2016; 6: 19413. https://doi.org/10.1038/srep19413
Savelyeva AV, Kuligina EV, Bariakin DN, et al. Variety of RNAs in peripheral blood cells, plasma, and plasma fractions. Biomed Res Int 2017; 2017: 7404912. https://doi.org/10.1155/2017/7404912
Jung YW, Shim JI, Shim SH, et al. Global gene expression analysis of cell-free RNA in amniotic fluid from women destined to develop preeclampsia. Medicine (Baltimore) 2019; 98: e13971. https://doi.org/10.1097/MD.0000000000013971
Lawson P, Sholl AB, Brown JQ, et al. Persistent homology for the quantitative evaluation of architectural features in prostate cancer histology. Sci Rep 2019; 9: 1139. https://doi.org/10.1038/s41598-018-36798-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
